Casi pharmaceuticals announces $15 million private placement financing by venrock healthcare capital partners, foresite capital, panacea venture and dr. wei-wu he

Beijing , june 26, 2024 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi) ("casi" or the "company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing (the "pipe transaction") that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fees and other private placement expenses. the pipe transaction is being led by venrock healthcare capital partners and foresite capital, with participation by panacea venture and dr. wei-wu he, the chairman of the board of directors and chief executive officer of the company and his family trust.
CASI Ratings Summary
CASI Quant Ranking